First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma.

ABSTRACT: Multiple myeloma (MM) remains incurable despite the number of novel therapies that have become available in recent years. Occasionally, a patient with MM will develop an amyloid light-chain (AL) amyloidosis with organ dysfunction. Chimeric antigen receptor T-cell (CART) therapy has become a promising approach in treating hematological malignancies. Our institution has developed a second-generation B-cell maturation antigen (BCMA)-CART which is currently being tested in a clinical trial for relapsed/refractory MM.We present the first reported case, to our knowledge, of a patient with AL amyloidosis and renal involvement in the course of an MM, successfully treated with CART therapy targeting BCMA. The patient received a fractioned dose of 3×10⁶/kg BCMA-CARTs after lymphodepletion

SUBMITTER: Oliver-Caldes A 

PROVIDER: S-EPMC8655576 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature